A disposable NT-proBNP sensor for managing heart failure at home
用于在家治疗心力衰竭的一次性 NT-proBNP 传感器
基本信息
- 批准号:9977701
- 负责人:
- 金额:$ 47.08万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:20 year oldAcuteAddressAdrenergic beta-AntagonistsAgeAgingAldosteroneAmbulatory CareAmerican Heart AssociationAntibodiesBiological AssayBiological MarkersBloodBlood GlucoseBuffersCardiologyCaringChronicClinicalClinical TreatmentCollaborationsCommunicationCommunitiesCountryDetectionDevelopmentDevice DesignsDevicesDiabetes MellitusDiagnosisDiagnosticDiseaseDiureticsEconomicsElderlyElectronicsEmergency department visitEmergency treatmentEnsureEuropeanFaceFinancial HardshipGlucoseGoalsGoldHealthcareHealthcare SystemsHeart failureHome environmentHospitalizationHumanIndividualInnovation CorpsInterventionLength of StayMeasurementMeasuresMedicalMedical Care CostsMedicareMedication ManagementMethodsMissionModelingMonitorMyocardialNatriuretic PeptidesNurse PractitionersOutcomePatient CarePatient Care ManagementPatient MonitoringPatientsPharmaceutical PreparationsPharmacologyPharmacotherapyPhysiciansPhysiologicalPilot ProjectsPlasmaPopulationPrevalenceProcessQuality of CareQuality of lifeReagentResearchResearch Project GrantsResourcesRouteSample SizeSamplingSerumSocietiesStressStretchingSystemSystolic heart failureTest ResultTestingTherapeuticTimeTitrationsTreatment FailureUnited StatesUnited States National Institutes of HealthVariantVasodilator AgentsVisitWireless TechnologyWorkagedaging populationbasebeneficiarycardiac resynchronization therapycardiovascular healthclinical decision-makingcollegecostdesigndiabeticeconomic costeconomic evaluationglucose monitorhealth economicsimprovedimproved outcomemortalitynew technologynovelpalliativepatient home carepatient populationpersistent symptompro-brain natriuretic peptide (1-76)programsprototypesensorstandard of carestatisticsstress managementtool
项目摘要
Project Summary/Abstract
More than 5 million individuals in the United States have clinically manifest Heart Failure (HF), and that number
continues to rise with the country's aging population contributing to serious strains on the healthcare system
and to huge economic costs. Diagnosing and managing the cardiovascular health concerns for such a large
population, particularly the elderly who often also suffer from diabetes, has created a growing need for new
healthcare paradigms that will help: (1) accommodate the physical challenges of aging and diabetic HF
patients and (2) lower medical cost and the strain on healthcare resources. Elevated levels of natriuretic
peptide biomarkers NT-proBNP and BNP indicate the presence of myocardial stress, and in people with HF,
these have been shown to correlate with acute exacerbations of this condition. Quantitation of natriuretic
peptide levels is critical to the determination of appropriate emergency and clinical treatment, and currently is
the only blood-based assay that exists for the diagnosis of myocardial stress and management of HF.
Studies where natriuretic peptides were used to guide drug therapies and diagnostics suggest reduced
mortality and a significantly lowered number and duration of hospital stays. The goal of this project is
development of a home-use sensing system that will allow HF patients to monitor their level of NT-proBNP at
home, in much the same way that diabetics monitor their blood glucose levels. The project builds on extensive
preliminary research that has resulted in a pre-prototype sensor design. At this very early stage in its
development, the sensor is able to detect NT-proBNP at levels near the range of clinical utility in buffer at the
lab bench. In the present proposal an ambitious plan is described to develop the sensor further and also to
develop detailed plans for incorporating it into a complete monitoring system. The quantitative result of the NT-
proBNP test would be available, via wireless technology, to the patient's cardiologist who may then remotely
adjust the patient's medications. Importantly, the goal of the work is to monitor patients who have already
been diagnosed with HF; that is, it is not intended as a diagnostic tool, but rather a patient care tool to help
guide appropriate therapy and create better outcomes.
The specific aims include development of a sensor platform capable of detecting NT-proBNP in whole
human blood over a dynamic range appropriate for NYHA class I-III HF patients. In collaboration with a
cardiologist, the sensor will be tested using blood from actual HF patients, and the resulting statistics will be
compared to those obtained using a gold-standard method. Finally, working with world-class consultants,
plans will be developed for a system design that incorporates the regulatory impacts and a health economics
analysis to identify the routes to reimbursement. The opportunity to improve clinical decision-making,
especially in relation to hospitalization and return to the community, directly addresses the NIH mission to
improve quality of care, reduce costs, and more closely couple physiological changes to medical intervention.
项目概要/摘要
在美国有超过 500 万人患有临床表现的心力衰竭 (HF),而这个数字
随着该国人口老龄化的加剧,医疗保健系统面临严重压力
并付出巨大的经济代价。诊断和管理如此大的心血管健康问题
人口,特别是经常患有糖尿病的老年人,对新产品的需求日益增长
医疗保健范式将有助于:(1) 适应衰老和糖尿病性心力衰竭的身体挑战
(2) 降低医疗成本和医疗资源压力。利尿钠水平升高
肽生物标志物 NT-proBNP 和 BNP 表明心肌应激的存在,并且在心力衰竭患者中,
这些已被证明与这种情况的急性恶化有关。尿钠定量
肽水平对于确定适当的紧急和临床治疗至关重要,目前
唯一用于诊断心肌应激和治疗心力衰竭的基于血液的检测方法。
使用利钠肽指导药物治疗和诊断的研究表明,
死亡率以及住院次数和住院时间显着降低。该项目的目标是
开发家用传感系统,使心力衰竭患者能够监测他们的 NT-proBNP 水平
在家中,就像糖尿病患者监测血糖水平一样。该项目建立在广泛
初步研究产生了预原型传感器设计。在其早期阶段
开发中,该传感器能够检测缓冲液中接近临床实用范围的水平的 NT-proBNP
实验台。在目前的提案中,描述了一个雄心勃勃的计划,以进一步开发传感器,并
制定详细计划,将其纳入完整的监测系统。 NT-的定量结果
proBNP 测试将通过无线技术提供给患者的心脏病专家,然后他们可以远程进行
调整患者的用药。重要的是,这项工作的目标是监测已经患有此病的患者
被诊断患有心力衰竭;也就是说,它并不是作为诊断工具,而是作为患者护理工具来帮助
指导适当的治疗并创造更好的结果。
具体目标包括开发能够全面检测 NT-proBNP 的传感器平台
人体血液的动态范围适合 NYHA I-III 级心力衰竭患者。与合作
心脏病专家将使用实际心力衰竭患者的血液对传感器进行测试,得出的统计数据将是
与使用金标准方法获得的结果进行比较。最后,与世界一流的顾问合作,
将制定系统设计计划,其中纳入监管影响和健康经济学
分析以确定报销途径。改善临床决策的机会,
特别是在住院和返回社区方面,直接解决了 NIH 的使命:
提高护理质量,降低成本,并将生理变化与医疗干预更紧密地结合起来。
项目成果
期刊论文数量(9)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Detection Efficiency of Ag Nanoparticle Labels for a Heart Failure Marker Using Linear and Square-Wave Anodic Stripping Voltammetry.
- DOI:10.3390/bios12040203
- 发表时间:2022-03-29
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Silver Nanocubes as Electrochemical Labels for Bioassays.
- DOI:10.1021/acssensors.0c02377
- 发表时间:2021-03-26
- 期刊:
- 影响因子:8.9
- 作者:Peng Y;Rabin C;Walgama CT;Pollok NE;Smith L;Richards I;Crooks RM
- 通讯作者:Crooks RM
Effect of Serum on Electrochemical Detection of Bioassays Having Ag Nanoparticle Labels.
- DOI:10.1021/acssensors.1c00446
- 发表时间:2021-05-28
- 期刊:
- 影响因子:8.9
- 作者:Pollok NE;Peng Y;Rabin C;Richards I;Crooks RM
- 通讯作者:Crooks RM
Paper Biosensor for the Detection of NT-proBNP Using Silver Nanodisks as Electrochemical Labels.
- DOI:10.3390/nano12132254
- 发表时间:2022-06-30
- 期刊:
- 影响因子:5.3
- 作者:Peng, Yi;Raj, Nikhil;Strasser, Juliette W.;Crooks, Richard M.
- 通讯作者:Crooks, Richard M.
Plastic-based lateral flow immunoassay device for electrochemical detection of NT-proBNP.
- DOI:10.1039/d2an00685e
- 发表时间:2022-05-30
- 期刊:
- 影响因子:4.2
- 作者:Raj, Nikhil;Crooks, Richard M.
- 通讯作者:Crooks, Richard M.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD M CROOKS其他文献
RICHARD M CROOKS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD M CROOKS', 18)}}的其他基金
A disposable NT-proBNP sensor for managing heart failure at home
用于在家治疗心力衰竭的一次性 NT-proBNP 传感器
- 批准号:
9353541 - 财政年份:2017
- 资助金额:
$ 47.08万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 47.08万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 47.08万 - 项目类别:
Standard Grant